Shots:

• The P-II Lauriet study evaluates the safety & efficacy of semorinemab (anti-tau mAb) vs PBO in 272 adult patients with AD across 43 centers globally. The therapy is being developed by Genentech
• The trial met its one co-1EPs i.e 43.6% reduction in cognitive decline from baseline as measured by ADAS-Cog11 @49wks. The 2EPs were not achieved for ADCS-ADL & no effect on other co-primary EPs of reducing the rate of functional decline from baseline as measured by ADCS-ADL or 2EPs for MMSE & CDR-SB
• Additionally- the safety profile was consistent with previous clinical data. Genentech to continue the open-label portion of the study & results will be submitted at CTAD in Nov’21

  | Ref: AC Immune | Image: AC Immune